Bioventus Quarterly Balance Sheet
NASDAQ: BVSHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bioventus financial position
As of Jun 27, 2026, Bioventus reported total assets of $673.3 million, down 4.7% from a year earlier against total liabilities of $395.9 million. Shareholders' equity stood at $228.3 million, or 33.9% of assets. The company held $29.5 million in cash and equivalents against $248.5 million of debt, a net debt position of $219.0 million.
The current ratio (current assets divided by current liabilities) was 1.69, meaning short-term assets cover obligations due within a year. Debt-to-equity was 1.09.
Summary generated from market data by MetaCap's automated system. Methodology
Bioventus balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-27 | Q1 20262026-03-28 | Q4 20252025-12-31 | Q3 20252025-09-27 | Q2 20252025-06-28 | Q1 20252025-03-29 | Q4 20242024-12-31 | Q3 20242024-09-28 | Q2 20242024-06-29 | Q1 20242024-03-30 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 29.46M | 35.85M | 51.24M | 42.16M | 32.91M | 22.80M | 41.58M | 43.07M | 31.99M | 25.17M | 36.96M | 26.83M |
| Receivables | 138.41M | 120.53M | 128.30M | 130.40M | 132.37M | 118.08M | 127.39M | 121.92M | 137.31M | 125.54M | 122.79M | 112.90M |
| Inventory | 79.81M | 83.19M | 82.24M | 96.27M | 96.47M | 94.05M | 92.47M | 90.03M | 87.61M | 97.00M | 91.33M | 97.56M |
| Total Current Assets | 257.53M | 249.81M | 272.84M | 280.90M | 275.20M | 249.37M | 275.61M | 298.69M | 308.88M | 265.90M | 268.00M | 249.45M |
| Property, Plant & Equipment | 20.53M | 21.29M | 21.90M | 22.98M | 24.51M | 25.72M | 27.01M | 29.43M | 31.94M | 34.53M | 36.60M | 39.70M |
| Goodwill | 7.46M | 7.46M | 7.46M | 7.46M | 7.46M | 7.46M | 7.46M | 7.46M | 7.46M | 7.46M | 7.46M | 7.46M |
| Intangible Assets | 351.05M | 359.66M | 368.42M | 377.40M | 386.95M | 395.73M | 404.73M | 414.81M | 424.55M | 470.67M | 482.35M | 493.32M |
| Long-Term Investments | 3.51M | 2.10M | 2.29M | 2.27M | 1.69M | 1.76M | 1.89M | 1.93M | 2.09M | 3.21M | 3.14M | 6.86M |
| Total Assets | 673.35M | 650.54M | 683.56M | 701.59M | 706.79M | 691.41M | 727.96M | 769.49M | 792.17M | 794.24M | 810.91M | 811.10M |
| Accounts Payable | 20.20M | 24.05M | 10.93M | 26.65M | 24.25M | 19.20M | 23.69M | 16.85M | 24.44M | 19.10M | 23.04M | 17.64M |
| Short-Term Debt | 18.75M | 18.75M | 15.00M | 11.25M | 43.36M | 37.34M | 27.34M | 38.57M | 38.57M | 35.81M | 27.85M | 19.58M |
| Total Current Liabilities | 152.45M | 148.09M | 160.38M | 161.75M | 185.68M | 174.75M | 210.40M | 211.49M | 231.46M | 173.32M | 175.50M | 160.84M |
| Long-Term Debt | 229.70M | 253.33M | 278.95M | 311.33M | 297.88M | 308.59M | 308.29M | 345.02M | 344.72M | 355.43M | 367.00M | 375.03M |
| Total Liabilities | 395.93M | 416.27M | 455.11M | 494.34M | 505.49M | 505.94M | 542.35M | 582.66M | 603.11M | 576.81M | 589.79M | 584.65M |
| Shareholders' Equity | 228.31M | 188.90M | 184.10M | 166.10M | 161.24M | 148.14M | 147.94M | 148.74M | 150.94M | 171.28M | 173.59M | 177.53M |
| Retained Earnings | -298.38M | -331.82M | -334.93M | -349.68M | -352.84M | -360.30M | -357.66M | -354.92M | -350.10M | -326.11M | -321.54M | -315.44M |
| Total Debt | 248.45M | 272.08M | 293.95M | 322.58M | 341.24M | 345.93M | 335.63M | 383.59M | 383.28M | 391.24M | 394.85M | 394.62M |
| Net Cash (Debt) | -219.00M | -236.23M | -242.71M | -280.42M | -308.33M | -323.13M | -294.05M | -340.51M | -351.29M | -366.07M | -357.88M | -367.79M |
This table shows 12 quarterly periods of Bioventus's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow BVS's reporting calendar. What is a balance sheet?